Please note, this OEL/ADE monograph also applies to Crinecerfont hydrochloride (CAS RN 321839-75-2), Crinecerfont tosylate (CAS RN 2649012-17-7). Crinecerfont is a corticotropin-releasing factor (CRF) type 1 receptor antagonist used as adjunctive treatment to glucocorticoid replacement requirements in adults and pediatric patients 4 years old and older with classic congenital adrenal hyperplasia (CAH). Crinecerfont free base is the S-enantiomer with an enantiomeric excess of at least 99.7%.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value and the Permitted Daily Exposure (PDE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Crinecerfont, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.